PubMed · 995292
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
W Montorsi. 1976-11-03. [Megaesophagus].. https://pubmed.ncbi.nlm.nih.gov/995292/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
We conducted a prospective, multicenter, randomized trial to compare the efficacy of sclerotherapy plus propranolol with that of propranolol alone in the prevention of recurrent gastroesophageal bleeding in severely cirrhotic patients. For 2 yr (1987 to 1988) 131 patients (96% of whom were alcoholic) with Child-Pugh class B or C cirrhosis (56% were class B and 44% were class C) were randomly assigned to one of our two treatment groups after cessation of variceal bleeding, without hemostatic sclerosis, and were observed for at least 2 yr. Treatment observance was good in 89% of cases; alcohol withdrawal was observed in 62% of cases. Sclerotherapy was performed weekly with 1% polidocanol, and variceal obliteration was obtained in 83% of cases, in a mean number of four sessions. The cumulative percentages (expressed as mean +/- S.D.) of recurrent bleeding at 2 yr were 42% +/- 6% for propranolol plus sclerotherapy and 59% +/- 6% for propranolol alone (a nonsignificant difference). Twenty-eight patients from the propranolol group but only 12 patients from the propranolol-plus-sclerotherapy group had recurrent bleeding from esophageal variceal rupture (p less than 0.01). The total number of blood units per patient with recurrent bleeding was slightly but not significantly more important in the propranolol group (8 +/- 7) than in the propranolol-plus-sclerotherapy group (5 +/- 5; p = 0.09).(ABSTRACT TRUNCATED AT 250 WORDS)
Lasers have contributed in a significant way to the evolution of therapeutic endoscopy. Their ability to coagulate and ablate tissue precisely has been applied to a wide variety of lesions in the upper gastrointestinal tract. Meanwhile, the number of nonlaser devices has also continued to expand, making it necessary to frequently reassess their respective roles. Available evidence suggests that current laser equipment is best suited for the palliative ablation of tumors, especially in the esophagus. On the other hand, the hemostatic properties of the laser are still indicated in the control of vascular malformations but have been largely displaced in the management of peptic ulcer disease by other, more convenient and less expensive methods. With a new generation of laser equipment likely to be introduced soon, these comparisons will undoubtedly need to continue for some time.